Our results suggest that patients with MPN who present with ACS and have a history of JAK2 mutation, prior CVD, have recently been diagnosed with MPN, and have leukocytosis at the time of ACS should be monitored closely for adverse cardiac events. The gene discussed is JAK2; the disease is myeloproliferative disorder.